Human Insulin from Recombinant DNA Technology
- 11 February 1983
- journal article
- research article
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 219 (4585) , 632-637
- https://doi.org/10.1126/science.6337396
Abstract
Human insulin produced by recombinant DNA technology is the first commercial health care product derived from this technology. Work on this product was initiated before there were federal guidelines for large-scale recombinant DNA work or commercial development of recombinant DNA products. The steps taken to facilitate acceptance of large-scale work and proof of the identity and safety of such a product are described. While basic studies in recombinant DNA technology will continue to have a profound impact on research in the life sciences, commercial applications may well be controlled by economic conditions and the availability of investment capital.Keywords
This publication has 5 references indexed in Scilit:
- A point mutation is responsible for the acquisition of transforming properties by the T24 human bladder carcinoma oncogeneNature, 1982
- Authenticity and Purity of Human Insulin (recombinant DNA)Diabetes Care, 1982
- Chemical, Physical, and Biologic Properties of Biosynthetic Human InsulinDiabetes Care, 1981
- Asilomar Conference on Recombinant DNA MoleculesScience, 1975
- Potential Biohazards of Recombinant DNA MoleculesScience, 1974